Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenomix-alfa
- Development stage
- Unknown
- Lead developer
- Bio-STILOGIT Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Adenomix-alfa is a multi-ingredient dietary supplement developed and marketed by Bio-STILOGIT Pharmaceuticals, primarily in Italy. It is formulated to support prostate health and the normal function of the urinary tract, particularly in the context of benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms. The product contains a combination of botanical extracts, including *Serenoa repens* (Saw Palmetto), *Urtica dioica* (Stinging Nettle), and *Boswellia serrata*, along with the mineral Zinc. *Serenoa repens* is recognized for its ability to inhibit 5-alpha-reductase, thereby reducing the conversion of testosterone to dihydrotestosterone (DHT), while *Boswellia* and *Urtica* provide anti-inflammatory effects by modulating leukotriene synthesis and other inflammatory mediators. Adenomix-alfa is sold as a retail consumer product and is not classified as a prescription pharmaceutical drug.
- Brand names
- Adenomix-alfa
02
Targets
Steroidogenesis (Steroidogenic enzymes)Eicosanoid synth (Eicosanoid biosynthesis)
Beyond the preview
Go deeper on Adenomix-alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenomix-alfa.